Program​​​​​​​​​​​

QSPC2026

  • The QSPC2026 program will consist of 11 plenary sessions with invited speakers from both academia and industry, with contributions from key opinion leaders as well as emerging investigators.The program will include several tutorial sessions on key emerging techniques and approaches in QSP.

  • QSPC will offer ample opportunities for scientific exchange and networking, through poster sessions, plenary trainee flash talks, social activities, tutorials, software demonstrations by exhibitors, and satellite workshops.

Detailed program

DAY 0: Tuesday, April 7, 2026

17:00 – 19:00 | Welcome reception

DAY 1: Wednesday, April 8, 2026

08:30 – 08:45 | Welcome & Opening Remarks

08:45 – 09:45 | Session 1: New Rules, New Models: Quantitative Science for Emerging Modalities

Chairs: Don Mager (University at Buffalo) & Tamara van Steeg (LAP&P)

  • Modeling the Disposition of Oligonucleotide Therapeutics (ASOs and GalNAc-siRNA) in Preclinical Species and Humans — Rodrigo Cristofoletti (University of Florida)

  • Navigating complexity: Opportunities and challenges in translational oncolytic virus modeling — Zinnia Parra-Guillen (BioInvent/Univ Navarra)

  • A translational mechanistic-QSP framework for predicting protein expression with mRNA therapeutics and vaccines — Rajat Desikan (GSK)

09:45 – 10:30 | Coffee Break

10:30 – 11:50 | Session 2: Immunology QSP: Actors to Partner with Drugs

Chairs: Dirk Jan Moes (LUMC) & Jeroen Elassaiss-Schaap (PD-value)

  • Pediatric QSP models for infliximab Treatment in IBD — Tomoyuki Mizuno (Cincinnati Children's Hospital Medical Center)

  • Multi-physiology modeling of the immune system in the era of precision immunotherapy — Kyemyung Park (Ulsan National Institute of Science and Technology)

  • QSP modeling of the immune response to vaccination — Jeff Sachs (MSD)

  • Flash talk

    • An Immunological QSP Model Incorporating Peptide-HLA Binding to Enable Characterization of CD4+ T-Cell Response Variability in the Clinic — Rory Marriott (Monash University)

    • A Multiscale Computational Platform Based on QSP and PBPK Modeling to Support the Development of mRNA-based Therapies — Elisa Pettinà (University of Trento)

    • A Quantitative Systems Pharmacology platform model of Ulcerative Colitis and combination therapies — Justin Feigelman (Gilead Sciences)

    • Development of a Physiologically Based Model of Bilirubin Metabolism in Health and Disease and Its Comparison with Real-World Data — Ahenk Zeynep Sayin (University Hospital RWTH Aachen)

    • A mechanistic model of P-glycoprotein binding kinetics untangles contradicting evidence on the expression-activity relationship – the future of IVIVE PBPK? — Daan van Valkengoed (Leiden University)

11:50 – 13:35 | Lunch & Poster Session I

13:35 – 14:55 | Session 3: QSP and AI/ML: Current Opportunities and Future Vision

Chairs: Robert Bies (University at Buffalo) & Sandra Visser (Quantivis LLC)

  • Improving precision through hybrid ML and QSP modeling: an example in immuno-oncology — Anna Kondic (Bristol Myers Squibb)

  • Addressing the QSP Knowledge Bottleneck with AI: Motivation and Design of QSP‑Copilot — Ali Farnoud & Anuraag Saini (Boehringer Ingelheim)

  • Reimagining QSP: AI/ML-Driven Multi-Modal Disease Modeling — Jane Knöchel (University of Copenhagen)

  • Flash talk

    • No One-Size-Fits-All: A Multi-Model Evaluation of Optimization-Based and Surrogate-Assisted Virtual Population Generation in QSP — Elena Righetti (University of Trento)

    • Faster Global Sensitivity Analysis with Neural ODE surrogates — Roberto Abbiati (Roche)

    • Network-Driven Characterization of Tertiary Lymphoid Structures in Inflammatory Bowel Disease — Amanda Clark (Oregon State University)

    • Translating Human Thyroid-on-a-Chip Data to Clinical Situations Using a Digital Twin PBPK-QST Modeling Framework — Cleo Demeester (ESQlabs GmbH)

    • TBD

14:55 – 16:10 | Coffee Break & Poster Session II

16:10 – 17:30 | Session 4: Integrating Micro-Physiological and Organ-on-Chip Systems with QSP

Chairs: Linda Aulin (Leiden University) & Holly Kimko (AstraZeneca)

  • Foundations of Micro-Physiological and Organ-on-Chip Systems — James Hickman (University of Central Florida/Hesperos)

  • Modeling Kidney Micro-Physiology: A Sex-Specific Perspective — Aurélie Carlier (Maastricht University)

  • Organ-on-Chip Data in Quantitative Systems Toxicology — Carmen Pin (AstraZeneca)

DAY 2: Thursday, April 9, 2026

08:30 – 09:10 | Session 5: Leveraging QSP Approaches for Rare Diseases Drug Development

Chairs: Inaki Troconiz (Navarra) & Susana Neves-Zaph (Sanofi)

  • From Mechanistic Understanding to Regulatory Approval: QSP Modeling in cTTP — Cameron McBride (Takeda)

  • Using QSP and virtual patients for biomarker identification and dose optimization in pediatric rare diseases — Luca Marchetti (Centre for Computational and Systems Biology)

09:10 – 09:50 | Session 6: Integrating CNS PBPK and QSP approaches

Chairs: Tingjie Guo (Leiden University) & Liesbeth de Lange (Leiden University)

  • The QSPainRelief model framework- the LeiCNS PBPK and binding kinetic models — Liesbeth de Lange (Leiden University)

  • The QSPainRelief model framework: the QSP neural circuit models on analgesia and side effects — Athan Spiros (In silico Biosciences)

09:50 – 10:35 | Coffee Break

10:35 – 11:55 | Session 7: Enhancing QSP Through Emerging Computational Methods

Chairs: Cesar Pichardo (AstraZeneca) & Laura Zwep (Leiden University)

  • Phase i trials in cancer: From board to bench to bedside and back again — Alexander Anderson (Moffitt)

  • Continuous infusion repeated sensitivity analysis - a new methodology for understanding mechanistic models — Wilbert de Witte (ESQlabs)

  • Learning the missing equations: Interpretable ML for mechanistic models of cancer — Sepinoud Azimi Rashti (TU Delft)

  • Flash talk

    • Model-Informed First-in-Human Dose Selection for an In Vivo BCMA CAR T Therapy in Multiple Myeloma — Christopher Morris (Certara)

    • A Systems Biology framework for the assessment of the therapeutic potential of NRF2 in NSCLC — Paul Cozmuta (Roche)

    • QSP Model-Based Patient Selection and Dosing Strategies for Tipifarnib and Alpelisib Combination in HRAS and PIK3CA-Dysregulated HNSCC — Amitava Mitra (Kura Oncology)

    • From rich preclinical datasets to virtual patients: a QSP framework to support the development of an ADC in AML — Simon Arsène (Nova in Silico)

    • QSP modelling of T-cell exhaustion as a driver of relapse in long-term treatment with T-cell engagers — Jonas Denk (Certara)

11:55 – 13:40 | Lunch & Poster Session III

13:40 – 15:00 | Session 8: Integrating Data for Global Health: A Systems Approach in Infectious Diseases

Chairs: Rada Savic (UCSF) & Rob van Wijk (Leiden University)

  • Building Translational Platforms: Integrating Preclinical and Clinical Systems Knowledge to Predict Efficacy in Anti-TB Drug Development — Rada Savic (UCSF)

  • Mechanism-Based Models to Link Target-Site Exposures to Parasite and Host Responses for Drugs against Neglected Tropical Diseases — Thomas Dorlo (Uppsala University)

  • Systems pharmacology modelling of multimodal data to combat antimicrobial resistance — Gauri Rao (University of Southern California)

  • Flash talk

    • A QSP approach for assessing pharmacological markers of HIV pre-exposure prophylaxis (PrEP) — Sara Iannuzzi (Freie Universität Berlin)

    • Next-generation mechanism-based mathematical model describing the response of twelve Pseudomonas aeruginosa strains with diverse resistance mechanisms to aztreonam, ciprofloxacin, and their synergistic combination therapy — Charlotte Picton (Monash University)

    • Quantitative Systems Pharmacology Modeling of Autophagy-Mediated Simvastatin Effect as a Host-Directed Therapy for Tuberculosis to Identify Translational Discrepancies — Bart van Lieshout (Leiden University)

    • A minimal PBPK model to predict PK and PD of pH-dependent FcRn binders with an optional albumin binding domain and translation across mouse, monkey and human — Tim Paulusse (Leiden University) and James Wade (Certara)

    • A mechanistic quantitative systems pharmacology model of atherosclerosis prospectively predicted LDL-C outcomes of the phase 3 CORALreef Lipids trial — Emmanuelle Bechet (Nova in Silico)

15:00 – 16:15 | Coffee Break & Poster Session IV

16:15 – 17:55 | Session 9: QSP in Regulatory Submissions: Success Stories, Opportunities, and Future Vision

Chairs: Britta Wagenhuber (Certara) & Andrea Manfrin (MHRA)

  • Leveraging QSP for Regulatory Submissions in Rare Diseases — Susana Neves-Zaph (Sanofi)

  • Regulatory QSP in Practice: Success Areas, Pain Points, Credibility Assessment, and Impact of AI — Liang Zhao (UCSF)

  • Uncertainty quantification methods for complex models used in drug development and/or regulatory approval — Andrew Hooker (Uppsala University)

  • Moving toward best practices for credibility assessment and reporting of QSP models in regulatory interactions — Blerta Shtylla (Pfizer/ISOP)

  • Panel disuccusion

19:00 – 22:00 | Conference diner

DAY 3: Friday, April 10, 2026

09:00 – 10:20 | Session 10: QSP-informed individualized patient care

Chairs: Catherijne Knibbe (Leiden University) & Anne-Grete Märtson (Leiden University)

  • Systems understanding to individualize dosing for obese populations — Elke Krekels (Certara)

  • Mechanistic Modelling to improve Patient Outcome in Pediatric Oncology — Rick Admiraal (Prinses Maxima Center)

  • QSP: what is the future for the clinic? — Andrea Edginton (Waterloo University)

  • Panel discussion: Next steps towards QSP-informed individualized patient care

10:20 – 11:05 | Coffee Break

11:05 – 12:15 | Session 11: Future of QSP

Chairs: Coen van Hasselt (Leiden University)

  • QSP in 2030: Where do we go from here — Piet van der Graaf (Certara/Leiden University)

  • Panel discussion

12:15 – 12:30 | Closing & Awards

Powered by
event registration made easy
 event registration made easy